<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04183660</url>
  </required_header>
  <id_info>
    <org_study_id>HVT-MB1</org_study_id>
    <nct_id>NCT04183660</nct_id>
  </id_info>
  <brief_title>A Post Market Surveillance Study of the Hemovent Extracorporeal Cardiopulmonary Support System of Cardiac and Respiratory Support: The MOBYBOX Trial</brief_title>
  <official_title>A Post Market Surveillance Study of the Hemovent Extracorporeal Cardiopulmonary Support System for Cardiac and Respiratory Support: The MOBYBOX Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hemovent GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>MAXIS Medical, LLC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hemovent GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate prospectively the safety and performance of the
      MOBYBOX System in the veno-arterial configuration in patients with cardiorespiratory failure
      or in the veno-venous configuration in patients with severe respiratory failure.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 2020</start_date>
  <completion_date type="Anticipated">February 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>30 Days</target_duration>
  <primary_outcome>
    <measure>Rates of device and procedure related serious adverse events</measure>
    <time_frame>24 hours</time_frame>
    <description>Acute safety defined as rates of device and procedure related serious adverse events up to 24 hours post-intervention.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Device performance success</measure>
    <time_frame>every 4 hours while the patient receives ECMO using the MOBYBOX device</time_frame>
    <description>Device performance success (defined as the ability to establish either veno-arterial ECMO to support cardiorespiratory function and tissue oxygenation or veno-venous ECMO to support respiratory function and tissue oxygenation)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Event rate</measure>
    <time_frame>24 hours</time_frame>
    <description>Acute safety defined as rates adverse events up to 24 hours post-intervention.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality rate</measure>
    <time_frame>30 days</time_frame>
    <description>All-cause mortality up to 30 days post-intervention</description>
  </secondary_outcome>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Cardiac Failure</condition>
  <condition>Respiratory Failure</condition>
  <condition>Cardio-Respiratory Failure</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MOBYBOX System</intervention_name>
    <description>extracorporeal cardiopulmonary support</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Consented patients with cardiorespiratory failure or ith severe respiratory failure who
        meet all of the inclusion and none of the exclusion criteria and in whom the investigator
        intends to treat the patient with cardiopulmonary support using the Hemovent MOBYBOX
        System.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosed with cardiac, respiratory or cardiorespiratory failure and 1 of the 5
             following sets of findings:

               1. A Murray score ≥ 3.0 and/or severe hypoxemia with A PaO2/FIO2 &lt; 100 mm on &gt; 0.9
                  FIO2;

               2. Uncompensated hypercapnia with pH &lt;7.2 despite a Pplateau &gt; 30 cm H20;

               3. Significant air leak/bronchopleural fistula;

               4. Need for intubation in a patient on lung transplant list;

               5. Immediate cardiac or respiratory collapse (pulmonary embolus, blocked airway,
                  unresponsive to optimal care);

          -  Written consent of the patient or the legal guardian or external consulting physician
             as designated and approved by the Ethics Committee.

        Exclusion Criteria:

          -  High pressure ventilation (FIO2 &gt; 0.9 and Pplateau &gt; 30 cm H2O) or high FIO2
             requirements for more than 7 days;

          -  Severe intracranial bleeding, which precludes the use of anticoagulation therapy or
             any other inability to be anticoagulated

          -  Excessive weight (&gt; 180 Kg)

          -  Severe irreversible brain injury (e.g., hypoxic brain injury)

          -  Inability to accept blood products;

          -  Any condition or organ dysfunction that would limit the likelihood of overall benefit
             from ECMO, such as severe, irreversible brain injury, hepatic and/or renal failure, or
             untreatable metastatic cancer;

          -  Immunosuppression with an absolute neutrophil count &lt; 400/mm3;

          -  Patient has been treated with ECMO ≤ 48 hours.

          -  For veno-veno ECMO in the setting of respiratory failure the following exclusion
             criteria apply:

          -  Severe pulmonary hypertension (mPAP &gt; 50 mm Hg)

          -  Severe right or left sided heart failure (EF &lt; 25%)

          -  For veno-arterial ECMO in the setting of cardiac insufficiency:

          -  Severe aortic regurgitation

          -  Aortic dissection.

          -  The patient is moribund, or the patient has severe or deteriorating damage in critical
             body systems.

          -  Patient is participating in an investigational drug or device study trial that has not
             reached the primary endpoint or that interferes with the current study endpoints.

          -  Any condition that in the judgment of the investigators would interfere with the
             subject's ability to provide informed consent, comply with study instructions, place
             the subject at increased risk, or which might confound interpretation of study
             results.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Phillipp Lepper, PD Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Uniklinikum Saarland</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yvonne Seibt</last_name>
    <phone>+49 69 2400 3626</phone>
    <email>yseibt@maxismedical.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Universitätsklinikum des Saarlandes</name>
      <address>
        <city>Homburg Saar</city>
        <state>Saarland</state>
        <zip>66484</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Phillipp Lepper, PD Dr.</last_name>
      <phone>+49 6841 162 3614</phone>
      <email>Phillipp.lepper@uniklinikum-saarland.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>November 27, 2019</study_first_submitted>
  <study_first_submitted_qc>November 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 3, 2019</study_first_posted>
  <last_update_submitted>February 13, 2020</last_update_submitted>
  <last_update_submitted_qc>February 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Insufficiency</mesh_term>
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

